Search

Displaying results 201 - 210 of 312 in total
  1. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion … Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor.

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  2. Drug

    Hydroxychloroquine

    go.drugbank.com/drugs/DB01611
    ApprovedInvestigational

    [L8072] A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.[A192546]

  3. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

    Categories: Orexin Receptor Antagonists
  4. Drug

    Mitomycin

    go.drugbank.com/drugs/DB00305
    ApprovedInvestigational

    [A193419] Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper

  5. Drug

    Cladribine

    go.drugbank.com/drugs/DB00242
    ApprovedInvestigational

    Cladribine is a purine analogue or a chlorinated derivative of adenine that causes apoptosis of B and T lymphocytes. Cladribine was first approved in the United States in 1993 initially as a treatment for a number of hematological malign...

  6. Drug

    Coagulation factor VII human

    go.drugbank.com/drugs/DB13150
    ApprovedInvestigational

    Coagulation factor VII is human serine protease type enzyme that is involved in the extrinsic coagulation cascade which results in blood clotting.

    Mixtures: UMAN COMPLEX, UMAN COMPLEX
  7. Drug

    Plasma protein fraction (human)

    go.drugbank.com/drugs/DB13968
    ApprovedInvestigational

    The plasma protein fraction human (PPFh) is defined as a sterile solution of proteins composed mainly of albumin and globulin derived from human plasma. It is already reviewed under the category of biologics by the FDA where the processi...

    Mixtures: UMAN SERUM
  8. Drug

    Lucanthone

    go.drugbank.com/drugs/DB04967
    Investigational

    One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46). It is currently being tested as a radiation sensitizer.

  9. Drug

    Methylene blue

    go.drugbank.com/drugs/DB09241
    ApprovedInvestigational

    Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Afr...

    Mixtures: Uta, Uta
  10. Drug

    Rosiglitazone

    go.drugbank.com/drugs/DB00412
    ApprovedInvestigational

    Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. … Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ

    Categories: Peroxisome Proliferator Receptor gamma Agonist, Peroxisome Proliferator-activated Receptor Activity